| Previous close | 1,452.00 |
| Open | 1,448.00 |
| Bid | 1,435.00 x 0 |
| Ask | 1,440.00 x 0 |
| Day's range | 1,432.00 - 1,456.00 |
| 52-week range | 1,296.00 - 3,175.00 |
| Volume | |
| Avg. volume | 1,153,681 |
| Market cap | 128.802B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -106.72 |
| Earnings date | 02 Aug 2024 - 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Mar 2015 |
| 1y target est | 2,212.50 |
GlobeNewswireNxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750. The milestone was achieved with clearance of the ORX750 Investigational New Drug application and progression of ORX750 into a Phase 1 clinical trial. ORX750
- GlobeNewswire
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
Expansion of existing partnership will utilize novel insights into causal biology within auto-immune disorders to identify novel targets for drug discovery Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) and PrecisionLife, the Causal AI precision medicine company, today announce the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
- GlobeNewswire
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants – see Neurocrine press announcement here. NB
